Furthermore, the expression of UBE2T (FANCT), which is needed for the ubiquitination of FANCI and which we have also shown to be upregulated in prostate cancer cells resistant to the anti-androgen therapy drug enzalutamide (45), was significantly reduced (Figure 2A, Supplementary Figure S4A). Here, UBE2T is linked to prostate cancer.